ENDURONYL
LOE ApproachingNDAORALTABLET
Approved
Aug 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ENDURONYL is an oral tablet NDA approved in 1961 by Abbott with unknown mechanism of action and pharmacologic class. The drug's indications, mechanism, and modality are not publicly documented in available data. Patient population and therapeutic use cannot be determined from current information.
LOE Approaching
ENDURONYL is in late-stage lifecycle with LOE approaching; commercial teams are likely focused on transition planning and cost-containment rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ENDURONYL offers limited career growth opportunity given its LOE-approaching status and zero linked job openings. Roles available are primarily defensive—managing market transition, generic competition, and portfolio wind-down rather than driving innovation or commercial expansion.
Brand ManagerSales Representative
Worked on ENDURONYL at Abbott? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.